Serologic correlates of protection for evaluating the response to meningococcal vaccines.
about
Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.Towards an improved serogroup B Neisseria meningitidis vaccine.N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines.Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B.Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Optimizing protection against meningococcal disease.Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.Relatively high serum vitamin D levels do not impair the antibody response to encapsulated bacteria.Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers.
P2860
Q34034071-B445BB55-D9FF-4A85-992E-541E058A94C7Q36265032-DAF98C7C-1C81-49E3-8EED-645F3503E4B3Q36314090-13A9323A-7ED2-4FFA-94C2-39A63C986ABEQ36327065-F4AADFB3-8159-4B53-A6E0-8BE6328C6ABDQ36445780-A2455FBD-AB45-4EB4-85C7-B84ED402B4CBQ36530211-80A7C5FA-7E8C-4B6B-8AE6-F5F52934BEAFQ36600323-D765662D-A37D-4BD5-BEB5-5C4A70CF2E5AQ36672529-3A72821A-7B48-42F5-8786-613F73FB5112Q37075472-54C3E7E4-A543-457C-B40B-92534D23A9B8Q37362174-3FAB51E1-9378-45AA-B690-9BB4BB17817AQ37514748-39FF5420-96F4-4575-8455-10A2321306CDQ37678717-296C1543-79CE-46CD-BB02-BDCEAFD029B1Q40408137-FBAD0274-E1EE-4563-80C2-B06FA24B9B4BQ42173007-7463E45A-F902-4267-8DE6-BF3BD8C9E27FQ44539393-317B3E8C-E4FA-4E65-A631-7AE25FF88004Q53762383-A149EA3E-17F7-41BD-958C-CE1B9EBB3749
P2860
Serologic correlates of protection for evaluating the response to meningococcal vaccines.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Serologic correlates of protection for evaluating the response to meningococcal vaccines.
@ast
Serologic correlates of protection for evaluating the response to meningococcal vaccines.
@en
type
label
Serologic correlates of protection for evaluating the response to meningococcal vaccines.
@ast
Serologic correlates of protection for evaluating the response to meningococcal vaccines.
@en
prefLabel
Serologic correlates of protection for evaluating the response to meningococcal vaccines.
@ast
Serologic correlates of protection for evaluating the response to meningococcal vaccines.
@en
P2860
P356
P1476
Serologic correlates of protection for evaluating the response to meningococcal vaccines.
@en
P2093
Paul Balmer
P2860
P356
10.1586/14760584.3.1.77
P50
P577
2004-02-01T00:00:00Z